{"id":"fixed-duration-higher-dose-hydrocortisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood disturbances"},{"rate":null,"effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrocortisone (cortisol) is an endogenous glucocorticoid that acts as an immunosuppressant and anti-inflammatory agent. It binds to intracellular glucocorticoid receptors, translocates to the nucleus, and alters gene expression to reduce production of pro-inflammatory cytokines and chemokines. The fixed-duration higher-dose formulation is designed to deliver elevated corticosteroid levels over a defined treatment period for acute inflammatory or critical conditions.","oneSentence":"Hydrocortisone is a glucocorticoid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and modulating cytokine production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:46.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute critical illness or sepsis (phase 3 investigational use)"},{"name":"Severe inflammatory conditions requiring short-term high-dose corticosteroid therapy"}]},"trialDetails":[{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fixed-duration higher dose Hydrocortisone","genericName":"Fixed-duration higher dose Hydrocortisone","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydrocortisone is a small molecule glucocorticoid receptor agonist, classified as an agonist. It has been studied in various clinical trials, including those for conditions such as respiratory insufficiency and acute lymphoblastic leukemia, often in combination with other interventions like ultra-protective ventilation facilitated by extracorporeal support.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}